Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment

Synaptic vesicle protein 2A (SV2A), the target of the antiepileptic drug levetiracetam (LEV), is expressed ubiquitously in all synaptic terminals. Its levels decrease in patients and animal models of epilepsy. Thus, changes in SV2A expression could be a critical factor in the response to LEV. Epilep...

Descripción completa

Detalles Bibliográficos
Autores principales: Contreras-García, Itzel Jatziri, Gómez-Lira, Gisela, Phillips-Farfán, Bryan Víctor, Pichardo-Macías, Luz Adriana, García-Cruz, Mercedes Edna, Chávez-Pacheco, Juan Luis, Mendoza-Torreblanca, Julieta G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145097/
https://www.ncbi.nlm.nih.gov/pubmed/33922424
http://dx.doi.org/10.3390/brainsci11050531